



Edelris and Galapagos announce extension of a multi-year research agreement

Lyon - February 18th, 2020 – Building upon the positive results of an ongoing research collaboration aimed at the production of jointly designed chemical libraries, Edelris and Galapagos announce today that they have agreed to extend their multi-year partnership .

Jean-Yves Ortholand, CEO of Edelris, said *"The decision from Galapagos to extend such a successful and multi-faceted collaboration is a great recognition of our client-oriented mindset and the dedication of our teams to successfully reaching the predefined objectives. We certainly look forward to delivering many additional innovative compounds with unique and very specific modalities, to support Galapagos in their screening efforts."*

"In order to address innovative and difficult biological targets, Galapagos has recognized the need for increased chemical space coverage as well as novel and biorelevant chemical matter. Edelris, through its proven track record, high-level creativity and cutting-edge technologies such as flow-photochemistry, has been the ideal partner towards this goal." added Didier Roche, CSO of Edelris.

Other terms of the collaboration, including scientific, technical and financial, were not disclosed.

About Edelris:

EDELRIIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural-mimetic screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELRIIS has a proven track record with chemistry and drug discovery expertise and provides novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

EDELRIIS has recently become a premier provider of ligand identification services, based upon an integrated affinity selection platform for the identification of ligands, from a unique and non-commercial deck of over 1 million compounds.

Many customers from pharmaceutical and biotechnology companies have already recognized the value and specificity of Edelris's offer, accessing either its experienced MedChem services or its innovative natural-mimetic Keymical Collections™.